FDA Draft Guidance for Print DTCA Less than Feared
On February 4, 2004, the FDA issued long-awaited draft guidance documents designed to improve communications to consumers and health care practitioners about health conditions and medical products. The most eagerly anticipated guidance concerns the acceptable alternatives to the lengthy, detailed, and technically-written “brief summary” of risk information for consumer-directed print advertisements for prescription drugs.
This article reviews the new guidance and includes comments from Jack E. Angel, Executive Director of the Coalition for Healthcare Communication and Harry Sweeney, CEO of Dorland Global Health Communications.
Read this article now. It’s FREE…
PMN32-03
Issue: Vol. 3, No. 2: February 2004
Word Count: 1319
Find other articles in related Topic Areas:
